Table 2 Maximum dose of valproic acid (VPA) received during the entire treatment perioda

From: A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

 

Maximum VPA dose (mg kg −1day−1)

 

(First cohort, N =10)

(Second cohort, N =19)

 

10

30

60

90

Number of patients

3

7

15

4

Median duration at maximum dose (days)

8

16

26

19

Temporary suspension (number of patients)

1

1

4

3

Dose reduction (number of patients)

1

4

5

3

Stopped VPA in advance (number of patients)b

3

7

6

2

  1. aOn 29 patients who actually started VPA assumption.
  2. bFive serious adverse events, 1 non-compliance, 12 treatment failures.
Back to article page